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ABSTRACT
Cortisol has a distinct circadian rhythm with low
concentrations at night, rising in the early hours of the
morning, peaking on waking and declining over the day
to low concentrations in the evening. Loss of this
circadian rhythm, as seen in jetlag and shift work, is
associated with fatigue in the short term and diabetes
and obesity in the medium to long term. Patients with
adrenal insufﬁciency on current glucocorticoid
replacement with hydrocortisone have unphysiological
cortisol concentrations being low on waking and high
after each dose of hydrocortisone. Patients with adrenal
insufﬁciency complain of fatigue, a poor quality of life
and there is evidence of poor health outcomes including
obesity potentially related to glucocorticoid replacement.
New technologies are being developed that deliver
more physiological glucocorticoid replacement
including hydrocortisone by subcutaneous pump,
Plenadren, a once-daily modiﬁed-release
hydrocortisone and Chronocort, a delayed and
sustained absorption hydrocortisone formulation that
replicates the overnight proﬁle of cortisol. In this
review, we summarise the evidence regarding
physiological glucocorticoid replacement with a focus
on relevance to paediatrics.
INTRODUCTION
Glucocorticoids are essential stress hormones that
regulate metabolic, cardiovascular and immuno-
logical homeostasis. Cortisol, synthesised in the
adrenal cortex, is the main glucocorticoid in
humans and deﬁciency may result in death from an
adrenal crisis. Glucocorticoids, and speciﬁcally
hydrocortisone (cortisol), have been used for the
treatment of primary and secondary adrenal insufﬁ-
ciency since the 1950s,1 and were rapidly shown to
improve prognosis.2 Glucocorticoid replacement
therapy has changed little since its ﬁrst use,
although there is a better understanding of the
hypothalamic-pituitary-adrenal (HPA) axis and the
importance of preserving the cortisol circadian
rhythm for health. Recent evidence suggests that
patients with adrenal insufﬁciency have poor health
outcomes potentially related to long-term excess
glucocorticoid therapy.3 4 This has led to the dev-
elopment of new treatment regimens and drug
formulations that attempt to provide more physio-
logical cortisol replacement.
CIRCADIAN RHYTHMS AND THE HPA AXIS
The HPA axis is a classical endocrine feedback
loop; hypothalamic corticotropin-releasing hormone
and arginine vasopressin stimulate pituitary release
of adrenocorticotrophic hormone (ACTH), which
in turn stimulates cortisol secretion, cortisol then
completes the loop through negative feedback at
both the hypothalamus and pituitary. The HPA axis
begins to function from week 6 of fetal life but is
quiescent throughout most of gestation.5 Close to
term, a rise in corticosteroid concentrations is
thought to support adaption to parturition and it is
possible that maternal or fetal stress, through
increasing glucocorticoid production, may trigger
preterm birth.6 The HPA axis is immature at birth,
although the elements of the circadian system are
present and even preterm infants will respond to
light and dark triggers.7 The development of the
neonatal and childhood cortisol circadian rhythms
has been variously reported (table 1). During the
ﬁrst weeks of life there is no evident circadian
rhythm, however, within 2 months from delivery
the HPA axis demonstrates a recognisable rhythm
with a cortisol peak in the early morning and nadir
at midnight and this resembles the adult circadian
rhythm by 9 months of age.8 Once established, the
cortisol circadian rhythm is similar through child-
hood and into adult life with minimal reported
differences with age and puberty. The HPA axis cir-
cadian rhythm is regulated by the central pace-
maker in the suprachiasmatic nucleus (SCN) of the
hypothalamus. The SCN rhythm has an approxi-
mate period of 24.2 hours, such that it requires a
daily resetting via the light/dark photoperiod to
maintain a 24-hour rhythm.9 In adults, serum corti-
sol concentration has a nadir at midnight, rises
from around 02:00–04:00 hours, peaks shortly
after waking, declines over the day and is quiescent
(though still with detectable cortisol concentra-
tions) from around 18:00–02:00 hours.10
Interestingly, there is an ACTH rise shortly before
waking that may be a trigger for waking and there
is some day-to-day higher central control of this,
such that people expecting to wake later in the day
have their cortisol peak correspondingly delayed.11
The HPA axis also displays an ultradian rhythm
with glucocorticoid pulses occurring approximately
every hour and a quarter.12 A number of factors
may inﬂuence the cortisol circadian rhythm and the
cortisol rhythm itself regulates metabolism and
human behaviour (ﬁgure 1). Most tissues in the
body possess clock genes that are synchronised by
the central pacemaker in SCN,13 and there is evi-
dence that the circadian rhythm of glucocorticoids
can act as a secondary messenger from the central
pacemaker to peripheral clock genes.14 Changes in
basal concentrations of steroids and disruption of
the rhythm are caused by stress such as infection,
and raised basal cortisol concentrations with loss of
the circadian variability are linked to psychiatric ill-
nesses including post-traumatic stress disorder and
depression.15 16
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Table 1 Previous publications on cortisol concentrations and circadian rhythm in neonates infants and children36 69–82
Study Age range
Number of
subjects
24 hours
profile Notes Study findings Study conclusions
Neonatal studies
Price et al69 Neonates 8 term Yes: 4
samples
Salivary sampling
longitudinal study term till
24 weeks age
Variable cortisol pattern
until average of 12 weeks
Circadian rhythm established
in first few months of life
Hindmarsh et al70 Neonates and
adults
10 term
10 preterm
10 adults
Yes: 930 and
1530 samples
Venous sampling Morning cortisol was
significantly higher than
afternoon in all groups
Diurnal rhythm seen in
neonates aged 3–4 days
Jonetz-Mentzel and
Wiedemann71
Neonates–18 years 687 healthy
children
No: one
sample
08:00–
10:00 hours
Venous Cortisol in neonates aged
5 days lower than other
age groups
Low cortisol in neonates aged
5 days reflects lack of circadian
rhythm
Santiago et al72 Neonates 9 term Yes Three salivary samples per
day collected on weeks 2,
4, 8, 12, 16, 20, 24
Circadian rhythm appeared
at median 8 weeks
No relationship to sleeping
through the night
Circadian rhythm in cortisol
appears earlier than previously
expected and as early as
2 weeks in some babies
Iwata et al73 Neonates 27 term Yes Eight salivary samples over
a 24-hour period
Non-circadian rhythm
Acrophase of cortisol
secretion linked to birth
time in infants <5 days of
age
Initial HPA axis activity
entrained to birth time rather
than day/night periodicity
Stroud et al74 Neonates 100 term No Longitudinal salivary testing
in cohort with/without
maternal smoking for 1
month
Cortisol higher in maternal
smoking neonates
Maternal smoking alters HPA
axis in neonates: epigenetic
alteration of glucocorticoid
receptor postulated
Studies in older children
Lashansky et al75 2 months–17 years 102 term No:
Synacthen
test
Cross-sectional
Synacthen-stimulated levels
Standard Synacthen test
demonstrated rapid cortisol
response
Cortisol response highest in
infants and postpubertal
de Weerth et al76 2–5 months 14 term Yes 5×salivary monthly Circadian patterns
depended significantly on
analysis
Circadian rhythm can be seen
from 2 months onwards
Wallace et al77 Median age
11 years
14 healthy Yes Serum samples every
20 min for 24 hours
Clear circadian rhythm
demonstrated for cortisol
and ACTH
No relationship to puberty
or sex
Normal circadian rhythm is
seen in children with similar
levels of cortisol secretion to
adults
Ghizzoni et al78 6–11 years 8 healthy
8 NCCAH
Yes Comparison of cortisol and
TSH curves
24-hour cortisol AUC not
different but NCCAH had
lower nocturnal cortisol
and higher nocturnal TSH
TSH and cortisol inversely
correlated. Blunted overnight
cortisol rise in NCCAH leads to
higher TSH
Knutsson et al79 2–18 years 235 healthy
children
Yes Venous cross-sectional with
longitudinal n=28
No differences between
males or females or age
groups or pubertal status
in circadian rhythm and
cortisol
Circadian rhythm and absolute
cortisol does not vary through
childhood or puberty
DeVile et al80 3–20 years 50 SAI Yes Venous Patients had a
non-physiological
mid-morning nadir
Thrice-daily hydrocortisone did
not adequately replicate the
circadian rhythm of cortisol in
patients
Hermida et al81 Prepubertal
children
135 children:
14 GHD
36 SS
57 VSS
28 NS
Yes Serum cortisol and GH
analysis
Similar circadian rhythm
for cortisol secretion seen
in all groups
The relationship between GH
and cortisol secretion is
unclear, and GH-deficient
children can have entirely
normal cortisol secretion
patterns
Peters et al36 5–9 years and
adults
29 SS
80 adults
Yes Serum cortisol profiles
Deconvolution analysis
Circadian pattern similar in
adults and children with
earlier nadir and slightly
higher peaks in children
Mean 24-hour cortisol
secretion
Adults 6.3 mg/m2/day
Children 8.0 mg/m2/day
Non-significant difference
Morning cortisol is a fair
reflection of adrenal
sufficiency in adults and
children, but care must be
taken when assessing nadir in
children (ie, for Cushing’s
disease)
Shirtcliff et al82 9–15 years 306 children
followed
longitudinally
Yes: 3
samples
Salivary cortisol followed
longitudinally
Stable intra-individual
circadian rhythm
Sex differences seen at
puberty
Circadian rhythm is strongly
individual and stable across
pubertal development
ACTH, adrenocorticotrophic hormone; AUC, area under the curve; GHD, growth hormone deficiency; HPA, hypothalamic-pituitary-adrenal; NCCAH, non-classical congenital adrenal
hyperplasia; NS, normal stature; SAI, secondary adrenal insufficiency; SS, idiopathic short stature; TSH, thyroid-stimulating hormone; VSS, very short stature <−3SDS.
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THE IMPACT OF DISRUPTING CIRCADIAN RHYTHMS
ON HEALTH
In jet lag and shift work, the diurnal activity of the individual is
shifted in time. In young men travelling across a 7-hour time
zone shift, it took up to 11 days for peak cortisol secretion
values to reset and 21 days to reset the nocturnal cortisol nadir.
These changes in HPA activity were accompanied by sleepless-
ness and nausea.17 Switching the sleep/awake patterns, as in
shift work, has more long-term consequences and is associated
with an increased incidence of obesity and diabetes mellitus.18
Shifting the sleep cycle by 12 hours results in insulin resist-
ance.19 Population studies have shown increased risk of coron-
ary events and cerebrovascular disease in shift workers, and a
potential link to cancer.20 There is a growing body of work
showing an association between sleep disturbance, lack of sleep
and an adverse metabolic proﬁle.21 In young adults subjected to
restricted sleep patterns, those placed on a simulated shift work
pattern not aligned to the normal day/night pattern showed
a reduction in insulin sensitivity and rise in high sensitivity
C-reactive protein (a marker of cardiovascular risk), which was
more marked in those with sleep restriction and misalignment
than sleep restriction alone.22 Work in pregnant women has
shown that even when pre-pregnancy body mass index is con-
trolled for, women with gestational diabetes mellitus have worse
sleep patterns and a higher tendency to obstructive sleep apnoea
than those without.23 Short-term disruption in sleep results in a
20% overall increase in cortisol secretion, and a damping of the
cortisol circadian rhythm.24 Cortisol is a key regulator of
glucose metabolism with elevated concentrations resulting in
reduced insulin sensitivity.25 Thus, the evidence points to loss of
the cortisol circadian rhythm being associated with an increased
incidence of obesity, diabetes mellitus and an increase in biomar-
kers of cardiovascular risk.
ADRENAL INSUFFICIENCY
Adrenal insufﬁciency is classiﬁed into primary, secondary and
tertiary, where primary is failure of the adrenal gland, secondary
failure of the pituitary and tertiary hypothalamic dysfunction
resulting in adrenal suppression commonly through chronic
exposure to glucocorticoids.26 The most common cause for
primary adrenal insufﬁciency in Western world adults is auto-
immune Addison’s disease, but the causes in children differ,
with congenital adrenal hyperplasia (CAH) being the most
important cause in preschool children and autoimmune
Addison’s disease appearing in adolescence.27 The goals of treat-
ment for adrenal insufﬁciency are to replace physiological corti-
sol concentrations.28 In CAH, there is the additional need to
suppress excess adrenal androgen production, which is a conse-
quence of the excess ACTH drive.29 Mutations in the CYP21A2
gene encoding the enzyme 21-hydroxylase account for 95% of
CAH cases.30 31 In 21-hydroxylase deﬁciency, failure in cortisol
synthesis results in reduced cortisol feedback and consequently
increased pituitary ACTH release, which in turn promotes over-
production of 17-hydroxyprogesterone, progesterone and
adrenal androgens. Replacement of cortisol switches off the
excess ACTH drive from the pituitary and reduces the overpro-
duction of adrenal androgens. The importance of replacing the
circadian rhythm of cortisol is most evident in CAH, where the
early morning increase in ACTH causes excess androgens on
waking, and current treatment regimens fail to fully control
androgens in the majority of paediatric and adult patients.32 33
CURRENT GLUCOCORTICOID THERAPY IN CHILDREN
The dosage of hydrocortisone used for adrenal replacement has
reduced over time.34 There has also been a move from twice-daily
dosing to thrice-daily dosing with some evidence of beneﬁt.35
More complex regimes with four times per day dosing, or dosing
with reversed circadian pattern or strict 8 hourly dosing patterns
are recommended by some paediatricians, but to date there has
been no deﬁnitive evidence of superiority of any of these regi-
mens and none of these regimens has replaced the physiological
proﬁle of cortisol in children or adults.36 Paediatric therapy for
adrenal insufﬁciency in Europe was surveyed in 2014 through the
European Society of Paediatric Endocrinologists.37 Although the
survey response was small (67 respondents), participants repre-
sented 16 countries, and the vast majority of prescribers were
using generic hydrocortisone either as crushed/dispersed tablets
or as specially manufactured (ie, unlicensed) formulations.
Manipulation of the doses was necessary as the standard tablet
for hydrocortisone is 10 mg, which is too large a dose for the
majority of children. Most paediatricians were prescribing hydro-
cortisone three times per day. In older children and adults, pred-
nisolone or dexamethasone was used by some, but these are
avoided in childhood because of their more potent effect on
growth. Treatment with hydrocortisone results in cortisol proﬁles
that are unphysiological, despite many different regimens being
used. Children treated with hydrocortisone experience several
spikes in cortisol concentrations over the day, often to supraphy-
siological concentrations, followed by prolonged periods of hypo-
cortisolaemia between doses.38 Some regimens leave children and
adults with low concentrations of cortisol over the evening, and
with most current regimens cortisol concentrations fall to
undetectable levels overnight, and do not rise again until the ﬁrst
dose of hydrocortisone has been absorbed.
Figure 1 Central clock input and
output in relation to circadian rhythms.
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HEALTH OUTCOMES IN CAH AND ADRENAL
INSUFFICIENCY
The most common cause of adrenal insufﬁciency in childhood
is CAH, so it is in this population that we have most knowledge
of health outcomes in children treated with glucocorticoid
replacement therapies. CAH is a complex condition, and even
with optimal treatment androgen concentrations are seldom
normal, and so it can be difﬁcult to distinguish the adverse
effects of glucocorticoid treatment from those of the disease
itself. In general, paediatric patients tolerate the cortisol proﬁle
achieved from hydrocortisone therapy well in the short term,
but there is increasing evidence for poor health outcomes in the
long term.32 33 In adult patients with acquired adrenal insufﬁ-
ciency, quality of life may be poor and an increased prevalence
of psychological morbidity is also reported. Both outcomes have
been related to hydrocortisone doses.39 40 In paediatric patients
with CAH, quality of life is reported to be reduced, with boys
and girls equally affected suggesting that this is not simply
related to either androgen excess in girls or associated disorders
of sex development.41 The reasons for poor quality of life are
likely to be multifactorial, but it is possible that abnormal gluco-
corticoid proﬁles may contribute to this adverse outcome.
Working memory performance is lower in children with CAH
than in unaffected relatives, leading to speculation that the
abnormal cortisol proﬁle in childhood may adversely affect cog-
nitive development.42 Children with CAH have an increased
prevalence of obesity, insulin resistance, elevated leptin concen-
trations, dyslipidaemia and impaired glucose metabolism.43–46 It
is likely that this is due, in part, to the supraphysiological doses
of glucocorticoid that are often required to achieve satisfactory
ACTH suppression in childhood. Pharmacogenetic studies
suggest that variability in glucocorticoid sensitivity and metabol-
ism may also affect hydrocortisone requirements and metabolic
outcomes.47–49 Adults with CAH remain shorter than the
normal population and short stature in patients with CAH is
associated with hypertension, suggesting that treatment in child-
hood impacts on long-term health in adult life.50
NEW GLUCOCORTICOID REPLACEMENT TECHNOLOGIES
Subcutaneous infusions of insulin have been used in diabetes for
many years and have potential advantages over discrete injec-
tions.51 Several researchers have tried similar technology to
infuse hydrocortisone over a 24-hour period in patients with
adrenal insufﬁciency. In open-label studies or case reviews, there
have been subjective improvements in quality of life and reduc-
tions in hospital admissions.52 The only blinded randomised
controlled trial showed no preference between infusion and oral
hydrocortisone in patients with Addison’s disease with pre-
existing good quality of life.53 In children with CAH, subcutane-
ous hydrocortisone infusions have been used to improve
androgen control during puberty, when altered hydrocortisone
pharmacokinetics and poor adherence make treatment particu-
larly challenging.54 Subcutaneous infusion therapy in adolescent
CAH males resulted in improved androgen proﬁles, but the
potential long-term beneﬁts on cardiovascular risk factors,
quality of life, learning and psychological well-being have yet to
be examined.55 56 The lack of large trials and case series is due
in part to the cost and complexity of switching a patient to an
infusion. A pump costs in the order of £2000,57 and the
patients and family need intensive training to be able to re-site
cannulae every 3 days, manage sick day rules through temporary
basal rates and deal with potential pump failure or blockage.53
With these hurdles, and without advantages that pumps in
diabetes seem to offer, it seems likely that pumps will remain a
specialised option in adrenal insufﬁciency for patients with very
speciﬁc needs. Advances in the diabetes ﬁeld in transdermal
infusion mechanisms and smaller pumps may in time make this
technology more accessible.58
Plenadren (Bailiwick of Jersey) is a modiﬁed-release hydrocor-
tisone with an outer coating layer that provides an immediate
release of the drug and an extended-release core. Plenadren pro-
vides a more extended serum proﬁle of cortisol compared with
immediate-release hydrocortisone. In adults, the licensed
regimen of a single morning dose of Plenadren gives similar cor-
tisol exposure to a thrice-daily regime of immediate-release
hydrocortisone, although Plenadren tends to provide higher
concentrations of cortisol in the late morning and lower in the
late evening than a conventional regime and overall has approxi-
mately 20% less bioavailability (ﬁgure 2).59–61 The expectation
is that a once-daily Plenadren regime will improve adherence
and quality of life, although this remains to be demonstrated in
blinded trials. Open-label studies with Plenadren have shown an
improvement in quality of life and reduction in central adiposity
in adult patients with adrenal insufﬁciency, and these changes
have been sustained at 12 months of treatment with improve-
ments in lipid proﬁle.62 Plenadren is not licensed for use in chil-
dren. A small case series of children with Addison’s disease
and secondary adrenal insufﬁciency, in whom manipulation of
hydrocortisone doses and frequency of dosing failed to
achieve satisfactory cortisol replacement, has suggested that
Plenadren may have a place in paediatric practice. However,
two to three Plenadren doses a day were required to maintain
acceptable cortisol concentrations during waking hours.63 For
the treatment of CAH, Plenadren is unlikely to control excess
androgens as the overnight rise in cortisol is not replicated,
and nocturnal dosing of Plenadren would expose patients to
high levels of during the quiescent period of the cortisol circa-
dian rhythm.
Chronocort is a product under development by Diurnal (UK).
The product is a modiﬁed-release hydrocortisone, but differs
from Plenadren in having a delayed and sustained absorption
proﬁle rather than an immediate- and sustained-release
proﬁle.64 Chronocort aims to replace physiological cortisol con-
centrations by dosing at morning and night such that the night-
time dose provides release of hydrocortisone in the early hours
of the morning providing a prewaking rise in cortisol levels.
A phase II open-label study of Chronocort in 16 adults with
CAH showed that a twice-daily regimen of Chronocort pro-
vided a similar cortisol rhythm and early morning peak to
physiological cortisol concentrations in healthy volunteers
(ﬁgure 2).65 Six months usage of Chronocort resulted in lower
24-hour, morning and afternoon 17-hydroxyprogesterone and
androstenedione androgens compared with conventional
therapy. Whether these short-term effects can be sustained and
what effect on overall health status this has in patients is the
subject of an ongoing phase III study for Chronocort.
CONCLUSIONS
The circadian rhythm of cortisol is important for health in
humans, and there is evidence of deleterious effect when this
rhythm is disrupted. Many of the symptoms that patients with
adrenal insufﬁciency complain of such as fatigue, sleep disturb-
ance and poor concentration are seen when the cortisol circa-
dian rhythm is disrupted in jetlag. It is therefore a reasonable
hypothesis that replacing cortisol in a circadian manner should
be superior to current therapy. This should be no less true in a
paediatric than adult population and the sleep cycle may be
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more important in a developing individual than adult.66
Improvements in biochemical, auxological and quality-of-life
measures were reported in a 12-month study of patients with
Addison’s disease treated with Plenadren.55 In the only double-
blind study of hydrocortisone infusion, there was no clear
impact on patients’ well-being despite this treatment offering
the beneﬁt of a physiological early morning rise in cortisol and
a smoother cortisol proﬁle; however, this was a small group of
patients with good baseline quality of life and the study may
have been underpowered to detect a change. In CAH, there is a
need for circadian therapy to suppress the overnight ACTH
drive and reduce androgen production. This is demonstrated by
case studies of hydrocortisone infusions in CAH and a phase II
study of Chronocort. Future studies will need to demonstrate
clinical beneﬁt associated with improved biochemical control of
CAH. Cortisol and cortisone concentrations in saliva and corti-
sol concentrations in dried blood spots are reported to be
robust measures of blood cortisol concentrations,67 and are par-
ticularly attractive for the study of new hydrocortisone formula-
tions in children.68 However, the relationship between cortisol
proﬁles and medium-term and long-term health outcomes is
likely to be complex. It is important to note that the majority of
data regarding physiological glucocorticoid replacement is from
adult patients and there is a need for further studies in paediat-
rics to better understand the needs of paediatric patients with
adrenal insufﬁciency.
Figure 2 (A) Cortisol concentrations
measured by LC-MS/MS in healthy
volunteers (mean, 10th and 90th
centile).64 (B) Cortisol concentrations
measured by immunoassay on three
times daily immediate-release
hydrocortisone 20–40 mg in adrenal
insufﬁciency patents (mean and 95%
CI).61 (C) Cortisol concentrations
measured by immunoassay on
once-daily Plenadren 20–40 mg in
patients with adrenal insufﬁciency
(mean and 95% CI).61 (D) Cortisol
concentrations measured by LC-MS/MS
on twice daily Chronocort with 20 mg
at 23:00 hours and 10 mg at
07:00 hours in patients with congenital
adrenal hyperplasia (mean and sem).65
Arrows on x-axis represent timing of
dosing. LC-MS/MS, liquid
chromatography-mass spectroscopy/
mass spectroscopy.
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